Skip to main content
Clinical Trials/NCT00609284
NCT00609284
Completed
Phase 3

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux

Groupe Oncologie Radiotherapie Tete et Cou5 sites in 1 country406 target enrollmentFebruary 15, 2008

Overview

Phase
Phase 3
Intervention
cetuximab
Conditions
HNSCC
Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Enrollment
406
Locations
5
Primary Endpoint
Progression free survival
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The aim of the trial is to study the efficacy of adding concomitant chemotherapy (carboplatin/5FU) to Erbitux-radiotherapy in patients with locally advanced head and neck cancer.

Registry
clinicaltrials.gov
Start Date
February 15, 2008
End Date
March 26, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx
  • Stage III - IV (T0-T4, N0-N2b, M0)
  • Not resected
  • Karnofsky PS\>=80
  • Informed consent signed

Exclusion Criteria

  • Contra indication to chemotherapy or cetuximab

Arms & Interventions

1

Radiotherapy 70Gy, Erbitux, Carboplatin-5FU

Intervention: cetuximab

1

Radiotherapy 70Gy, Erbitux, Carboplatin-5FU

Intervention: Carboplatin, 5FU concomitant

1

Radiotherapy 70Gy, Erbitux, Carboplatin-5FU

Intervention: Radiotherapy

2

Radiotherapy 70Gy, Erbitux

Intervention: cetuximab

2

Radiotherapy 70Gy, Erbitux

Intervention: Radiotherapy

Outcomes

Primary Outcomes

Progression free survival

Time Frame: 3 years

Secondary Outcomes

  • Loco-regional control(3 years)

Study Sites (5)

Loading locations...

Similar Trials